CM101 stimulates cutaneous wound healing through an anti-angiogenic mechanism

被引:19
作者
Nanney L.B. [1 ,2 ,7 ]
Wamil B.D. [4 ,7 ]
Whitsitt J. [3 ,7 ]
Cardwell N.L. [1 ,7 ]
Davidson J.M. [3 ,7 ]
Yan H.-P. [6 ,7 ]
Hellerqvist C.G. [4 ,5 ,7 ]
机构
[1] Department of Plastic Surgery, Vanderbilt School of Medicine, Nashville, TN
[2] Department of Cell Biology, Vanderbilt School of Medicine, Nashville, TN
[3] Department of Pathology, Vanderbilt School of Medicine, Nashville, TN
[4] Department of Biochemistry, Vanderbilt School of Medicine, Nashville, TN
[5] Department of Medicine, Vanderbilt School of Medicine, Nashville, TN
[6] Department of Biology, Vanderbilt School of Medicine, Nashville, TN
[7] Vanderbilt School of Medicine, Nashville, TN
关键词
Angiogenesis; CM101; Endothelium; Laser doppler perfusion; Wound healing;
D O I
10.1023/A:1016752925761
中图分类号
学科分类号
摘要
CM101, an anti-pathoangiogenic polysaccharide derived from group B streptococcus, has been shown to inhibit inflammatory angiogenesis and accelerate wound healing in a mouse model and minimize scarring/gliosis following spinal cord injury. To evaluate the in vivo effects of CM101 on cutaneous wound healing in the pig, intravenously delivered CM101 or placebo vehicle was given 1 h after cutaneous wounding and again at 72 h after injury. Tissues from partial-thickness and full-thickness excisions were collected at days 4 and 7 after wounding and evaluated for a variety of standard healing parameters. Both types of CM101-treated wounds showed significantly less evidence of inflammatory angiogenesis when assessed by macroscopic photography of the wound surface, qualitative histological observations, laser doppler perfusion imaging, and quantitative morphometric analysis of microvessel area from endothelium selectively immunostained for factor VIII. Resurfacing was accelerated in partial-thickness and full-thickness excisions that received two doses of CM101 as compared to the placebo-treated excisional wounds. Neodermal thickness was increased in CM101-treated wounds at day 4 and was slightly reduced in comparison with placebo by day 7. New collagen accumulation appeared to be unaffected by the CM101 treatment. Immunohistochemical staining using a polyclonal antisera directed against the anti-pathoangiogenic CM101 target protein HP59 on day 7 indicated a strong immunoreactivity on the microvessels present in the control wounds but not in wounds of the CM101-treated animals. In summary, the immunolocalization HP59 in the microvessels of the cutaneous wound bed in control but not in CM101 treated wounds suggests that CM101 inhibits the pathologic inflammatory angiogenesis accompanying the normal granulation processes. The net biological effect of inhibited inflammatory pathoangiogenesis is a diminished, suggested and purely physiologic, microvascular bed which translates into an enhanced rate of epithelial resurfacing and therefore an overall accelerated rate of wound repair.
引用
收藏
页码:61 / 70
页数:9
相关论文
共 47 条
[31]  
Yan H.-P., Carter C.E., Wang E., Et al., Functional studies on the antipathoangiogenic properties of CM101, Angiogenesis, 2, pp. 219-233, (1998)
[32]  
Wamil B.D., Thurman G.B., Sundell H.W., Et al., Soluble e-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial, J Cancer Res Clin Oncol, 123, pp. 173-179, (1997)
[33]  
DeVore R.F., Hellerqvist C.G., Wakefield G.B., Et al., Phase I study of the antineovascularization drug CM101, Clinical Can Res, 3, pp. 365-372, (1997)
[34]  
Quinn T.E., Thurman G.B., Sundell A.-K., Et al., CM101, a polysaccharide anti-tumor agent, does not inhibit wound healing in murine models, J Can Res Clin Oncol, 121, pp. 253-256, (1995)
[35]  
Abramovitch R., Frenkiel D., Meir G., Et al., Mapping neovascularization and anti-neovascularization therapy: Correlation between NMR and light microscopy, Proceedings of the 5th Conference of the International Society of Magnetic Resonance in Medicine (ISMRM), (1997)
[36]  
Hellerqvist C.G., Neeman M., Wamil B.D., Abramovitch R., Facilitation of wound healing with CM101/GBS toxin, (1999)
[37]  
Vetvicka V., Thornton B.P., Ross G.D., Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells, J Clin Invest, 98, pp. 50-61, (1996)
[38]  
Schaffer C.J., Reinisch L., Polis S.L., Et al., Comparisons of wound healing among excisional, laser-created, and standard thermal burns in porcine wounds of equal depth, Wound Repair Regen, 5, pp. 52-61, (1997)
[39]  
Nanney L.B., Epidermal and dermal effects of epidermal growth factor during porcine wound repair, J Invest Dermatol, 94, pp. 624-629, (1990)
[40]  
Nanney L.B., Paulsen S., Davidson M., Et al., Boosting of EGF receptorsa by gene gun stimulates epidermal growth in vivo, Wound Repair Regen, 8, pp. 117-127, (2000)